CA2860994A1 - Methods of treating melanoma with pak1 inhibitors - Google Patents

Methods of treating melanoma with pak1 inhibitors Download PDF

Info

Publication number
CA2860994A1
CA2860994A1 CA2860994A CA2860994A CA2860994A1 CA 2860994 A1 CA2860994 A1 CA 2860994A1 CA 2860994 A CA2860994 A CA 2860994A CA 2860994 A CA2860994 A CA 2860994A CA 2860994 A1 CA2860994 A1 CA 2860994A1
Authority
CA
Canada
Prior art keywords
melanoma
pak1
inhibitor
braf
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2860994A
Other languages
English (en)
French (fr)
Inventor
Klaus P. Hoeflich
Adrian M. Jubb
Hartmut Koeppen
Christy C. Ong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2860994A1 publication Critical patent/CA2860994A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2860994A 2012-03-16 2013-03-13 Methods of treating melanoma with pak1 inhibitors Abandoned CA2860994A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612202P 2012-03-16 2012-03-16
US61/612,202 2012-03-16
PCT/EP2013/055085 WO2013135745A1 (en) 2012-03-16 2013-03-13 Methods of treating melanoma with pak1 inhibitors

Publications (1)

Publication Number Publication Date
CA2860994A1 true CA2860994A1 (en) 2013-09-19

Family

ID=47846052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2860994A Abandoned CA2860994A1 (en) 2012-03-16 2013-03-13 Methods of treating melanoma with pak1 inhibitors

Country Status (10)

Country Link
EP (1) EP2844248A1 (pt)
JP (1) JP2015511598A (pt)
KR (1) KR20140135198A (pt)
CN (1) CN104168898A (pt)
BR (1) BR112014020173A8 (pt)
CA (1) CA2860994A1 (pt)
HK (1) HK1200093A1 (pt)
MX (1) MX2014010953A (pt)
RU (1) RU2014141018A (pt)
WO (1) WO2013135745A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139331A1 (en) * 2015-03-05 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of melanoma
KR101730595B1 (ko) 2015-03-18 2017-05-11 충북대학교 산학협력단 Pak4 억제제를 유효성분으로 포함하는 미백 및 멜라닌 색소 과다 침착 질환의 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
DE3546806C2 (pt) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2090860C (en) 1990-11-21 2003-09-16 Richard A. Houghten Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0760012A4 (en) 1994-06-10 1997-07-02 Symbiotech Inc METHODS FOR DETECTING COMPOUNDS BY MEANS OF GENETICALLY MODIFIED LAMBDA BACTERIOPHAGE
US5627024A (en) 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
WO1997009446A1 (en) 1995-09-07 1997-03-13 Novo Nordisk A/S Phage display for detergent enzyme activity
ATE278958T1 (de) 1996-03-20 2004-10-15 Dyax Corp Reinigung des gewebe plasminogenaktivators (tpa)
JP2000512981A (ja) 1996-06-06 2000-10-03 ラ ホヤ ファーマシューティカル カンパニー ａＰＬ免疫応答性ペプチド、その結合体およびａＰＬ抗体媒介病理のための処置方法
AU735015B2 (en) 1996-06-10 2001-06-28 Scripps Research Institute, The Use of substrate subtraction libraries to distinguish enzyme specificities
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
EP0929361A4 (en) 1996-10-04 2000-07-19 Whatman Inc DEVICE AND METHOD FOR SIMULTANEOUS MULTIPLE SYNTHESIS
JP2001512560A (ja) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
DE69737415T2 (de) 1996-11-06 2007-10-31 Genentech, Inc., South San Francisco Gespannte, helixformende peptide und verfahren um sie herzustellen
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
ES2304531T3 (es) 2002-07-17 2008-10-16 Pfizer Italia S.R.L. Derivados heterobiciclicos de pirazol como inhibidores de quinasa.
NZ556273A (en) 2005-01-10 2010-01-29 Pfizer Pyrrolopyrazoles, potent kinase inhibitors
RU2007140734A (ru) 2005-04-06 2009-05-20 Астразенека Аб (Se) Замещенные гетероциклы и их применение в качестве ингибиторов chki, pdki и pak
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
MY151455A (en) 2005-12-21 2014-05-30 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
US20100317715A1 (en) 2007-12-21 2010-12-16 Vollrath Benedikt Methods for treating neuropsychiatric conditions
ES2306630B1 (es) 2008-07-17 2009-06-03 Encarnacion Mira Rodriguez Dispositivo antiflacidez y antiarrugas.
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
EP2485727A4 (en) 2009-10-06 2013-05-01 Afraxis Inc PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES
JP2013507395A (ja) 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
US20130231348A1 (en) 2010-06-09 2013-09-05 Afraxis, Inc. 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
US8912203B2 (en) 2010-06-09 2014-12-16 Afraxis Holdings, Inc. 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
US20130252967A1 (en) 2010-06-10 2013-09-26 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
EP2580217A4 (en) 2010-06-10 2014-06-18 Afraxis Holdings Inc 6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
WO2011156775A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

Also Published As

Publication number Publication date
BR112014020173A8 (pt) 2017-07-11
BR112014020173A2 (pt) 2017-06-20
WO2013135745A1 (en) 2013-09-19
HK1200093A1 (en) 2015-07-31
KR20140135198A (ko) 2014-11-25
MX2014010953A (es) 2014-10-13
RU2014141018A (ru) 2016-05-10
JP2015511598A (ja) 2015-04-20
EP2844248A1 (en) 2015-03-11
CN104168898A (zh) 2014-11-26

Similar Documents

Publication Publication Date Title
US11676731B2 (en) Diagnostic and therapeutic methods for the treatment of breast cancer
US20190125735A1 (en) Inhibition of p38 mapk for the treatment of cancer
AU2014364520A1 (en) Methods and assays relating to circulating tumor cells
US20240068047A1 (en) Use of sdha as a prognostic marker and therapeutic target in uveal melanoma
US20180011102A1 (en) The protein kinase activity of phosphoglycerate kinase 1 as a target for cancer treatment and diagnosis
US20230383365A1 (en) Cancer treatments and methods of selecting same
WO2018161081A1 (en) Gene signatures to predict drug response in cancer
Sun et al. miR‑489‑3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2
Borneman et al. Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
CA2860994A1 (en) Methods of treating melanoma with pak1 inhibitors
US20140275201A1 (en) Identification of cancer stem cell markers and use of inhibitors thereof to treat cancer
WO2020092924A1 (en) Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer
US20230076415A1 (en) Methods and compositions for treating melanoma
EP3775206A1 (en) Methods and pharmaceutical compositions for treating cancer
US20220220565A1 (en) Methods and compositions for treating melanoma
US20230416830A1 (en) Methods and compositions for predicting and treating uveal melanoma
LEPORE SIGNORILE p38α, the β-catenin chromatin associated kinase, as promising target in colorectal cancer stem cells for personalized therapy
Avinery et al. Hsp70–Bag3 Module Regulates Macrophage Motility and Tumor Infiltration via Transcription Factor LITAF and CSF1. Cancers 2022, 14, 4168
Vena MEK inhibition in pancreas cancer
Triscott Polo-like kinase 1 as a prognostic and therapeutic target in high-grade brain tumors
Greensmith Novel approaches in the management of bladder cancer
MANI et al. Sommaire du brevet 3010101

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170314